Gerostate Alpha (YC S18)
A pharmaceutical company dedicated to treating aging and age-related disease
Last Funded November 2021
$564,622
raised from 472 investors
Pitch Video
Investor Panel
Highlights
1
💵 $2.1M raised in initial seed round, at $15M valuation cap
2
🧬 Team at the forefront of aging research for decades, collectively authoring 200+ papers
3
💪 Our platform delivers drug candidates to slow aging at a success rate of 20%
4
🐭 Funds will be used to test our candidates in aging mice
Our Team
CEO
PhD; Professor at Buck Institute for Research on Aging & CEO of Gerostate Alpha
We know how to stop the threat of chronic disease; and we care because aging is 100% fatal
CTO
PhD; Expert in small molecule and genetic screens including significant experience with high throughput technologies, and has utilized simple model organisms to explore pharmacological extension of lifespan.
Gordon LithgowProfessor, Vice President Buck Institute
PhD; Chief Academic Officer at the Buck Institute for Research on Aging and specializes in the properties of small molecules to extend lifespan, having been internationally recognized for his work on aging with numerous awards and prizes.